Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33886306)
Watch
English
Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer.
scientific article
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
title
Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
author name string
Rena Callahan
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
publication date
1 March 2014
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
published in
Journal of the advanced practitioner in oncology
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
volume
5
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
issue
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
page(s)
134-139
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
cites work
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Cancer statistics, 2013
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Trastuzumab emtansine for HER2-positive advanced breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Adjuvant trastuzumab in HER2-positive breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Molecular portraits of human breast tumours
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4093506
retrieved
5 July 2018
Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25032047
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.6004/JADPRO.2014.5.2.5
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
PMC publication ID
4093506
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
PubMed publication ID
25032047
1 reference
stated in
Europe PubMed Central
PMC publication ID
4093506
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25032047%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
